Polyclonal antibody hyperGAMCF

Drug Profile

Polyclonal antibody hyperGAMCF

Latest Information Update: 10 Jul 1996

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Class Antibacterials; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 10 Jul 1996 North American Biologicals is now called NABI
  • 10 Jul 1996 Discontinued-II for Cystic fibrosis-associated respiratory tract infections in USA (IV)
  • 10 Jul 1996 Discontinued-II for Pseudomonal infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top